Results 261 to 270 of about 4,508,328 (306)
Some of the next articles are maybe not open access.

Molecular pharmacology of protein kinases

Neurochemical Research, 1990
Apercu des differents inhibiteurs et des activateurs de plusieurs proteines kinases etudies par les auteurs, leurs approches biochimiques et pharmacologiques et leurs applications cliniques ...
H, Hidaka, M, Hagiwara, T, Chijiwa
openaire   +2 more sources

Molecular pharmacology of somatostatin receptors

Fundamental & Clinical Pharmacology, 1995
Summary—Somatostatin was discovered for its ability to inhibit growth hormone (GH) secretion. Later, it was found to be widely distributed in other brain regions, in which it fulfills a neuromodulatory role, and in several organs of the gastrointestinal tract where it can act as a paracrine factor or as a true circulating factor.
C, Viollet   +8 more
openaire   +2 more sources

Clinical Pharmacology in the Molecular Era

Clinical Pharmacology & Therapeutics, 2008
The title of this article may raise a smile from colleagues in the field of basic pharmacology. To them, pharmacology has always been about molecular interactions, and this title may simply confirm a suspicion that clinical pharmacology is mainly about semi-quantitative observations that have only a limited foundation in hard science.
openaire   +2 more sources

Molecular pharmacology of P2Y-receptors

Naunyn-Schmiedeberg's Archives of Pharmacology, 2000
Membrane-bound P2-receptors mediate the actions of extracellular nucleotides in cell-to-cell signalling. P2X-receptors are ligand-gated ion channels, whereas P2Y-receptors belong to the superfamily of G-protein-coupled receptors. So far, the P2Y family is composed of eight cloned and functionally defined subtypes.
I, von Kügelgen, A, Wetter
openaire   +2 more sources

The molecular pharmacology of L-deprenyl

European Journal of Pharmacology: Molecular Pharmacology, 1992
L-Deprenyl, the selective inhibitor of monoamine oxidase type B (MAO-B), has gained wide acceptance as a useful form of adjunct therapeutic drug in the treatment of Parkinson's disease. This review summarizes the molecular pharmacology of L-deprenyl, and the advances in our understanding of its possible mode of action in Parkinson's disease. L-Deprenyl
M, Gerlach, P, Riederer, M B, Youdim
openaire   +2 more sources

Molecular Pharmacology of β-Adrenoceptors

Journal of Cardiovascular Pharmacology, 1986
The development of radioligand-binding studies has greatly advanced our knowledge of the molecular pharmacology of beta-adrenoceptors. With this technique it is possible for the first time to directly determine the tissue concentration of beta-adrenoceptors, and by this, the responsiveness of tissues to beta-adrenergic stimulation.
openaire   +2 more sources

Pharmacologic Vitreodynamics and Molecular Flux

2009
Several enzymatic agents, such as autologous plasmin enzyme and recombinant microplasmin, are able to cause vitreous liquefaction and a complete posterior vitreous detachment (PVD). Advancements in research have helped to explain the complex interactions that occur in the vitreous cavity after a PVD is created.
David T, Goldenberg, Michael T, Trese
openaire   +2 more sources

Molecular pharmacology of estrogens

Pharmacology & Therapeutics, 1979
S J, Segal, S S, Koide
openaire   +2 more sources

Stereoselectivity and Affinity in Molecular Pharmacology

1976
Just 100 years ago Crum-Brown and Fraser [1], in stating their conviction that biological activity must in some way be related to the structure of the agent causing it, laid the basis for all subsequent work on structure-activity relationships (S.A.R.).
P. A. Lehmann F.   +2 more
openaire   +2 more sources

Molecular biology of pharmacologic vitreolysis

American Journal of Ophthalmology, 2006
Pharmacologic vitreolysis is a promising new therapy to improve vitreoretinal surgery and, ultimately, prevent disease by mitigating the contribution of vitreous to retinopathy. The mechanism of action of the agents being developed for pharmacologic vitreolysis remains unclear.
openaire   +2 more sources

Home - About - Disclaimer - Privacy